Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 9
Submit an article Journal homepage
167
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Treatment failure cost analysis of Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation

Julian Lindsaya National Centre for Infection in Cancer, Peter MacCallum Cancer Centre, Melbourne, Australia;b Haematology Department, Royal North Shore Hospital, Sydney, Australia;c Vaccine and Infectious Disease and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7086-538XView further author information
ORCID Icon,
Matthew Greenwoodb Haematology Department, Royal North Shore Hospital, Sydney, Australia;d Northern Blood Research Centre, Kolling Institute of Medical Research, University of Sydney, Sydney, New South Wales, AustraliaView further author information
,
Jad Othmanb Haematology Department, Royal North Shore Hospital, Sydney, AustraliaView further author information
,
Sharon C.-A. Chene Centre for Infectious Diseases and Microbiology Laboratory Services, Institute of Clinical Pathology and Medical Research, New South Wales Health Pathology, Westmead Hospital, The University of Sydney, and the Marie Bashir Institute for Infectious Diseases and Biosecurity, Sydney, AustraliaView further author information
,
David C. M. Kongf NHMRC National Centre for Antimicrobial Stewardship at The Peter Doherty Institute for Infections and Immunity, Parkville, Victoria, Australia;g Faculty of Pharmacy and Pharmaceutical Sciences, Centre for Medicine Use and Safety, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia;h Pharmacy Department, Ballarat Health Services, Ballarat, Victoria, AustraliaORCID Iconhttps://orcid.org/0000-0002-5022-9060View further author information
ORCID Icon,
Steven A. Pergamc Vaccine and Infectious Disease and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;i Division of Allergy & Infectious Diseases, University of Washington, Seattle, Washington, USAORCID Iconhttps://orcid.org/0000-0002-6333-5196View further author information
ORCID Icon,
Catherine Liuc Vaccine and Infectious Disease and Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;i Division of Allergy & Infectious Diseases, University of Washington, Seattle, Washington, USAView further author information
&
Monica A. Slavina National Centre for Infection in Cancer, Peter MacCallum Cancer Centre, Melbourne, Australia;j Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia;k Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, AustraliaORCID Iconhttps://orcid.org/0000-0002-8443-314XView further author information
ORCID Icon show all
Pages 2254-2256 | Received 11 Feb 2022, Accepted 01 Apr 2022, Published online: 15 Apr 2022

References

  • Teira P, Battiwalla M, Ramanathan M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127(20):2427–2438.
  • Green ML, Leisenring W, Xie H, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3(3):e119-27–e127.
  • Ljungman P, de la Camara R, Robin C, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(8):e260–e272.
  • Hakki M, Aitken SL, Danziger-Isakov L, et al. American society for transplantation and cellular therapy series: #3-prevention of cytomegalovirus infection and disease after hematopoietic cell transplantation. Transplant Cell Ther. 2021;27(9):707–719.
  • Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in Hematopoietic-Cell transplantation. N Engl J Med. 2017;377(25):2433–2444.
  • Marty FM, Ljungman PT, Chemaly RF, et al. Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation. Am J Transplant. 2020;20(6):1703–1711.
  • National Institute of Health and Care Excellence. Letermovir for preventing cytomegalovirus disease after a stem cell transplant. Technology appraisal guidance [TA591]; 2019. Available from: https://www.nice.org.uk/guidance/ta591.
  • Merck & Co. Inc. Merck receives FDA approval of PREVYMIS™ (letermovir) for prevention of Cytomegalovirus (CMV) Infection and disease in adult allogeneic stem cell transplant patients; 2017 [cited 2022 Mar 23]. https://www.merck.com/.
  • Lindsay J, Othman J, Kerridge I, et al. Cytomegalovirus (CMV) management in allogeneic hematopoietic cell transplantation: pre-transplant predictors of survival, reactivation, and spontaneous clearance. Transpl Infect Dis. 2021;23(3):e13548.
  • IHPA. Australian refined diagnosis related groups version 10.0; 2019 [cited 2021 Oct 28]. Available from: https://www.ihpa.gov.au/.
  • NSW Health. Health purchasing New South Wales tender; 2019 [cited 2021 Oct 28]. Available from: www.tenders.nsw.gov.au.
  • Yong M, Tio SY, Valentine J, et al. The economic and health utilization cost of clinically significant cytomegalovirus infection following allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2020;26(3):S333–S334.
  • El Haddad L, Ghantoji SS, Park AK, et al. Clinical and economic burden of pre-emptive therapy of cytomegalovirus infection in hospitalized allogeneic hematopoietic cell transplant recipients. J Med Virol. 2020;92(1):86–95.
  • Chen J, Abella Ross J, Tegtmeier B, et al. Cost analysis of ganciclovir and foscarnet in recipients of allogeneic hematopoietic cell transplant with cytomegalovirus viremia. Transpl Infect Dis. 2020;22(2):e13233.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.